Risk factor
Very poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
DaBomb Protein Biotech Corp. is a specialized biotechnology enterprise primarily dedicated to developing and commercializing antibiotic replacements for the animal health industry. Its extensive product range includes plant-based proteins such as DaBomb-P (Aqua) and DaBomb-P (Livestock), alongside specific antibiotic alternative solutions like DBT-100 HT and DBT-100 LS. The company also manufactures pet care products, featuring LACTOTIDES HEALTH A+ and Liqui-TIDE bandages. Founded in 2001 and headquartered in Tainan, Taiwan, the firm adopted its current name, DaBomb Protein Biotech Corp., in October 2023, having previously operated as DaBomb Protein Corp.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.